Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
PMID: 28697251, DOI: 10.1001/jama.2017.7225
It belongs to a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP- 1), which also includes Mounjaro (tirzepatide), Ozempic (semaglutide), and Wegovy (semaglutide)
Sobo helps appropriate patients understand whether GLP-1 weight loss therapy may fit their history, goals, and risk factors
Contact our team to discuss your project
October 2023: JAMA Research Letter Warns of Possible Ozempic Risks A research letter filed in the Journal of the American Medical Association alleges the risk of adverse gastrointestinal events associated with the use of GLP-1 agonists that are used not only to treat diabetes but also off-label for weight loss
US$ 24.14
US$ 21.36
US$ 20.42
